- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT00132769
A Study of a Novel Investigational Drug in Rheumatoid Arthritis Patients (MK-0873-012)(COMPLETED)
29. juli 2015 oppdatert av: Merck Sharp & Dohme LLC
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind, 12-Week Study to Assess the Clinical Efficacy, Safety, and Tolerability of MK-0873 in Rheumatoid Arthritis
This study will look at whether this new drug is effective in the treatment of rheumatoid arthritis, and at whether it is safe and well-tolerated by participants with the disease.
Studieoversikt
Status
Fullført
Forhold
Intervensjon / Behandling
Studietype
Intervensjonell
Registrering (Faktiske)
106
Fase
- Fase 2
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
18 år til 65 år (Voksen, Eldre voksen)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Alle
Beskrivelse
Inclusion Criteria:
- Rheumatoid arthritis, according to the American College of Rheumatology criteria, with active disease despite current medications
- Other criteria also apply
Exclusion Criteria:
- Other major illnesses
- Past history of certain other disorders
- Certain prohibited medications
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Dobbelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: MK-0873
MK-0873 1.25 mg twice daily for 12 weeks
|
MK-0873 1.25 mg twice daily for 12 weeks
|
Placebo komparator: Placebo
Matching placebo to MK-0873 1.25 mg twice daily for 12 weeks
|
Matching placebo to MK-0873 1.25 mg twice daily for 12 weeks
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Change From Baseline in Swollen Joint Count
Tidsramme: Baseline and the average of Treatment Weeks 8, 10 and 12
|
Swollen joint count (SJC) was determined by assessing 66 joints (33 right side, 33 left side) for swelling using the following grading system: 0=Absent, 1=Detectable synovial thickening without loss of bony contours, 2=Loss of distinctiveness of bony contours, or 3=Bulging synovial proliferation with cystic characteristics.
The total number of joints graded 1, 2, or 3 were then counted to yield the SJC.
SJC ranged from 1-66, with increasing score indicating greater number of swollen joints.
SJC was averaged over weeks 8, 10 and 12 to yield a Treatment Period Mean.
Change from Baseline = Treatment Period Mean SJC - Baseline SJC.
|
Baseline and the average of Treatment Weeks 8, 10 and 12
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Percentage of Participants With American College of Rheumatology 20% Response [ACR20]
Tidsramme: Baseline and the average of Treatment Weeks 8, 10 and 12
|
Participants were categorized as meeting ACR20 criteria when they had at least 20% improvement from Baseline in tender and swollen joint counts, and improvement from Baseline in at least 3 of 5 of the following domains: Pain Visual Analog Scale (VAS), Patient Global Assessement, Physician Global Assessment, Patient Physical Function (Disability) Score and acute-phase reactant (Erythrocyte Sedimentation Rate [ESR] or C-Reactive Protein [CRP]).
The average percentage of participants that met the ACR20 responder criteria over Treatment Weeks 8, 10 and 12 was calculated.
|
Baseline and the average of Treatment Weeks 8, 10 and 12
|
Change From Baseline in Tender Joint Count
Tidsramme: Baseline and the average of Treatment Weeks 8, 10 and 12
|
Tender joint count (TJC) was to be determined by assessing 68 joints (34 right side, 34 left side) for pain using the following grading system: 0=No pain, 1=Patient states that there is pain, 2=Patient states that there is pain and winces, or 3=Patient states that there is pain, winces, and withdraws.
The total number of joints graded 1, 2, or 3 were then to be counted to yield the TJC.
TJC ranges from 1-68, with increasing score indicating greater number of tender joints.
TJC was to be averaged over weeks 8, 10, and 12 to yield a Treatment Period Mean.
Change from Baseline = Treatment Period Mean TJC - Baseline TJC.
|
Baseline and the average of Treatment Weeks 8, 10 and 12
|
Patient Global Assessment of Disease Activity
Tidsramme: The average of Treatment Weeks 8, 10 and 12
|
At each clinic visit, participants were to assess disease activity using a 100 mm visual analog scale (VAS) in reponse to the question: "Considering all the ways your arthritis affects you, mark an (X) through the line for how well you are doing."
The VAS ranges from "Very Well" (0) to "Very Poor" (100).
The mean score at Treatment Weeks 8, 10 and 12 was calculated.
A lower score indicates a better disease activity.
|
The average of Treatment Weeks 8, 10 and 12
|
Investigator Global Assessment of Disease Activity
Tidsramme: Treatment Week 12
|
At each clinic visit, the Investigator was to make a global assessment of participant disease activity on a 5-point Likert scale with grading as follows: 1=Very well, 2=Well, 3=Fair, 4=Poor, or 5=Very poor (scale range: 1-5).
A lower score indicates a more positive assessment of participant disease activity.
|
Treatment Week 12
|
Patient Global Assessment of Response to Therapy
Tidsramme: Treatment Week 12
|
Participants were to rate their overall response to the study drug on a 5-point Likert scale with grading as follows: 0=None, 1=Poor, 2=Fair, 3=Good, or 4=Excellent (scale range: 0-4).
A higher score indicates a more positive response to study drug.
|
Treatment Week 12
|
Health Assessment Questionnaire Disability Index
Tidsramme: The average of Treatment Weeks 8, 10 and 12
|
The Stanford Health Assessment Questionnaire Disability Index assesses participant functional ability based on 20 questions in 8 categories of functioning: dressing, rising, eating, walking, hygiene, reach, grip, and usual activities.
Responses range from 0=No disability to 3=Completely disabled.
The score for each category subscale is the single response within the category with the highest score (greatest difficulty).
The overall score for the Disability Index is the mean of the 8 category scores and also ranges from 0-3, with a lower score indicating less disability.
|
The average of Treatment Weeks 8, 10 and 12
|
Patient's Assessment of Pain
Tidsramme: Treatment Week 12
|
At each clinic visit, participants were to assess their amount of pain due to arthritis during the previous 48 hours on a 100 mm visual analog scale (VAS) that ranged from "No pain" (0) to "Extreme pain" (100).
A lower score indicates less pain.
|
Treatment Week 12
|
Ratio of On-treatment C-Reactive Protein to Baseline C-Reactive Protein
Tidsramme: Baseline and the average of Treatment Weeks 8, 10 and 12
|
C-reactive protein levels rise in response to inflammation in the body.
The ratio of On-treatment serum C-reative protein:Baseline serum C-reactive protein was calculated to determine a treatment effect.
On-treatment C-reactive protein = the mean of serum C-reactive protein levels for Treatment Weeks 8, 10 and 12.
A ratio of less than 1.0 is consistent with lower inflammation and was to be considered an improvement.
|
Baseline and the average of Treatment Weeks 8, 10 and 12
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart
1. januar 2005
Primær fullføring (Faktiske)
1. november 2005
Studiet fullført (Faktiske)
1. november 2005
Datoer for studieregistrering
Først innsendt
2. august 2005
Først innsendt som oppfylte QC-kriteriene
19. august 2005
Først lagt ut (Anslag)
22. august 2005
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
30. juli 2015
Siste oppdatering sendt inn som oppfylte QC-kriteriene
29. juli 2015
Sist bekreftet
1. juli 2015
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 0873-012
- 2005_029 (Annen identifikator: Telerex Study Number)
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på MK-0873
-
Merck Sharp & Dohme LLCAvsluttetLungesykdommer | Lungesykdom, kronisk obstruktiv
-
Merck Sharp & Dohme LLCFullført
-
Merck Sharp & Dohme LLCFullførtPsoriasis | Plakk PsoriasisForente stater
-
ArQule, Inc. (a wholly owned subsidiary of Merck...FullførtAvanserte solide svulsterForente stater
-
ArQule, Inc. (a wholly owned subsidiary of Merck...FullførtAdenokarsinom | BukspyttkjertelkreftForente stater
-
Merck Sharp & Dohme LLCAvsluttet
-
Merck Sharp & Dohme LLCFullførtType 2 diabetes mellitus
-
Merck Sharp & Dohme LLCFullførtHypertensjon | Isolert systolisk hypertensjon (ISH)
-
Merck Sharp & Dohme LLCFullført
-
Merck Sharp & Dohme LLCTilbaketrukket